Redeye: Calliditas Therapeutics: Progress made in Q4 – focus is on execution going forward

Calliditas is progressing according to plan with the NEFIGARD Phase III study. We provide an update on recent events.

Read more and download the analysis: 

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.